These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 10529381)
21. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Losen M; Martínez-Martínez P; Phernambucq M; Schuurman J; Parren PW; De Baets MH Ann N Y Acad Sci; 2008; 1132():174-9. PubMed ID: 18567867 [TBL] [Abstract][Full Text] [Related]
22. Acquired rippling muscle disease associated with mild myasthenia gravis: a case report. van Schaik SM; Kwa VI; van der Kooi AJ J Neurol; 2009 Jul; 256(7):1187-8. PubMed ID: 19277764 [No Abstract] [Full Text] [Related]
31. Muscle lymphocytic infiltrates in thymoma-associated myasthenia gravis are phenotypically different from those in polymyositis. Zamecnik J; Vesely D; Jakubicka B; Simkova L; Pitha J; Schutzner J; Mazanec R; Vogel H Neuromuscul Disord; 2007 Dec; 17(11-12):935-42. PubMed ID: 17651972 [TBL] [Abstract][Full Text] [Related]
32. Correlating extent of neuromuscular instability with acetylcholine receptor antibodies. Farrugia ME; Jacob S; Sarrigiannis PG; Kennett RP Muscle Nerve; 2009 Apr; 39(4):489-93. PubMed ID: 19260064 [TBL] [Abstract][Full Text] [Related]
33. Autoantibodies against TRPC3 and ryanodine receptor in myasthenia gravis. Takamori M J Neuroimmunol; 2008 Aug; 200(1-2):142-4. PubMed ID: 18602703 [TBL] [Abstract][Full Text] [Related]
34. [On the problem of the immunopathogenesis of myasthenia gravis: studies on organ specificity and antigenicity of human and animal skeletal muscle protein]. Ricken D; Stroehmann I; Aulepp H Verh Dtsch Ges Inn Med; 1968; 74():500-3. PubMed ID: 4977256 [No Abstract] [Full Text] [Related]
37. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Tzartos SJ; Bitzopoulou K; Gavra I; Kordas G; Jacobson L; Kostelidou K; Lagoumintzis G; Lazos O; Poulas K; Sideris S; Sotiriadis A; Trakas N; Zisimopoulou P Ann N Y Acad Sci; 2008; 1132():291-9. PubMed ID: 18567880 [TBL] [Abstract][Full Text] [Related]
38. Rippling muscle disease may be caused by "silent" action potentials in the tubular system of skeletal muscle fibers. Lamb GD Muscle Nerve; 2005 May; 31(5):652-8. PubMed ID: 15742369 [TBL] [Abstract][Full Text] [Related]
39. [Thymectomy and muscle antibodies in myasthenia gravis]. Romi F; Gilhus NE; Aarli JA Tidsskr Nor Laegeforen; 2004 Mar; 124(5):629-31. PubMed ID: 15004605 [TBL] [Abstract][Full Text] [Related]
40. [The evidence of antibodies against motor endplates of the skeletal muscle in myasthenia gravis with the double immune-fluorescence technique (author's transl)]. Storch W; Trautmann B Acta Histochem; 1981; 69(1):18-22. PubMed ID: 6795885 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]